TW202329984A - 作為急性肝紫質症（ａｈｐ）之生物標記的腎損傷生物標記 - Google Patents
作為急性肝紫質症（ａｈｐ）之生物標記的腎損傷生物標記 Download PDFInfo
- Publication number
- TW202329984A TW202329984A TW111137690A TW111137690A TW202329984A TW 202329984 A TW202329984 A TW 202329984A TW 111137690 A TW111137690 A TW 111137690A TW 111137690 A TW111137690 A TW 111137690A TW 202329984 A TW202329984 A TW 202329984A
- Authority
- TW
- Taiwan
- Prior art keywords
- therapeutic agent
- biomarker
- individual
- ahp
- kidney injury
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 427
- 208000033552 hepatic porphyria Diseases 0.000 title claims abstract description 196
- 208000003914 Acute hepatic porphyria Diseases 0.000 title claims abstract description 195
- 108700016481 Acute Hepatic Porphyria Proteins 0.000 title claims abstract description 194
- 206010061481 Renal injury Diseases 0.000 title claims description 144
- 238000000034 method Methods 0.000 claims abstract description 107
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims description 195
- 229940124597 therapeutic agent Drugs 0.000 claims description 179
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 116
- 108010051335 Lipocalin-2 Proteins 0.000 claims description 108
- 208000037806 kidney injury Diseases 0.000 claims description 105
- 102100040055 Amyloid beta precursor like protein 1 Human genes 0.000 claims description 87
- 101000890407 Homo sapiens Amyloid beta precursor like protein 1 Proteins 0.000 claims description 85
- 108020004707 nucleic acids Proteins 0.000 claims description 61
- 102000039446 nucleic acids Human genes 0.000 claims description 61
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 53
- 150000003278 haem Chemical class 0.000 claims description 44
- 239000008103 glucose Substances 0.000 claims description 39
- 230000035772 mutation Effects 0.000 claims description 37
- 210000003734 kidney Anatomy 0.000 claims description 36
- 230000006378 damage Effects 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 31
- 108091030071 RNAI Proteins 0.000 claims description 30
- 230000009368 gene silencing by RNA Effects 0.000 claims description 30
- 208000010642 Porphyrias Diseases 0.000 claims description 28
- 230000001154 acute effect Effects 0.000 claims description 27
- 208000024891 symptom Diseases 0.000 claims description 27
- 241000097929 Porphyria Species 0.000 claims description 26
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 24
- 229940025294 hemin Drugs 0.000 claims description 24
- 210000002381 plasma Anatomy 0.000 claims description 23
- 239000000523 sample Substances 0.000 claims description 23
- 230000001965 increasing effect Effects 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 230000001684 chronic effect Effects 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- -1 arginine heme Chemical class 0.000 claims description 16
- 210000003608 fece Anatomy 0.000 claims description 16
- 210000002700 urine Anatomy 0.000 claims description 16
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 15
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 15
- 102100027211 Albumin Human genes 0.000 claims description 14
- 108010088751 Albumins Proteins 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 239000008121 dextrose Substances 0.000 claims description 14
- 230000024924 glomerular filtration Effects 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 230000000306 recurrent effect Effects 0.000 claims description 10
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 claims description 9
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 9
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 9
- 102000003960 Ligases Human genes 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 206010062237 Renal impairment Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 2
- 102100026897 Cystatin-C Human genes 0.000 claims 8
- 102100030417 Matrilysin Human genes 0.000 claims 8
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims 8
- 102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 claims 7
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 claims 7
- 238000009987 spinning Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 12
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 102000004318 Matrilysin Human genes 0.000 description 112
- 108090000855 Matrilysin Proteins 0.000 description 112
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 108
- 102000012192 Cystatin C Human genes 0.000 description 104
- 108010061642 Cystatin C Proteins 0.000 description 104
- 102000013519 Lipocalin-2 Human genes 0.000 description 100
- 125000003729 nucleotide group Chemical group 0.000 description 77
- 239000002773 nucleotide Substances 0.000 description 74
- 108090000623 proteins and genes Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 37
- 230000000692 anti-sense effect Effects 0.000 description 31
- QSHWIQZFGQKFMA-UHFFFAOYSA-N Porphobilinogen Natural products NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 30
- YPHQRHBJEUDWJW-UHFFFAOYSA-N porphobilinogen Chemical compound NCC1=NC=C(CCC(O)=O)[C]1CC(O)=O YPHQRHBJEUDWJW-UHFFFAOYSA-N 0.000 description 30
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 21
- 206010036182 Porphyria acute Diseases 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 239000002243 precursor Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 11
- 229950010941 givosiran Drugs 0.000 description 10
- 108091081021 Sense strand Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 101150038201 ALAS1 gene Proteins 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 101000843649 Homo sapiens 5-aminolevulinate synthase, nonspecific, mitochondrial Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 238000012286 ELISA Assay Methods 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 102000056533 human ALAS1 Human genes 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 150000004032 porphyrins Chemical class 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 4
- 102100030755 5-aminolevulinate synthase, nonspecific, mitochondrial Human genes 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 102000004330 Rhodopsin Human genes 0.000 description 4
- 108090000820 Rhodopsin Proteins 0.000 description 4
- 230000009798 acute exacerbation Effects 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000000575 proteomic method Methods 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000010553 ALAD Human genes 0.000 description 3
- 101150082527 ALAD gene Proteins 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 101710168919 Amyloid beta precursor like protein 1 Proteins 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 230000009946 DNA mutation Effects 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 102000007343 Hepatitis A Virus Cellular Receptor 1 Human genes 0.000 description 3
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 3
- 101100016698 Homo sapiens ALAS1 gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 101150055960 hemB gene Proteins 0.000 description 3
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 3
- 208000013810 inherited porphyria Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940055741 panhematin Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002342 ribonucleoside Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000006794 tachycardia Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010008796 Chromaturia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 2
- 206010021036 Hyponatraemia Diseases 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- 102400001263 NT-proBNP Human genes 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- ZHWLPDIRXJCEJY-UHFFFAOYSA-N alpha-hydroxyglycine Chemical compound NC(O)C(O)=O ZHWLPDIRXJCEJY-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 1
- UOOOPKANIPLQPU-XVFCMESISA-N 3'-CMP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 UOOOPKANIPLQPU-XVFCMESISA-N 0.000 description 1
- FOGRQMPFHUHIGU-XVFCMESISA-N 3'-UMP Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-XVFCMESISA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- 101710184696 5-aminolevulinate synthase, nonspecific, mitochondrial Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UOOOPKANIPLQPU-UHFFFAOYSA-N Cytidylic acid B Natural products O=C1N=C(N)C=CN1C1C(O)C(OP(O)(O)=O)C(CO)O1 UOOOPKANIPLQPU-UHFFFAOYSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150034920 Hmbs gene Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100230720 Mus musculus Alas1 gene Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical class NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000037340 Rare genetic disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QXWJIJPOAPZARX-KQYNXXCUSA-N [(2r,3r,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 QXWJIJPOAPZARX-KQYNXXCUSA-N 0.000 description 1
- QGZHQRNBDZDKFW-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O[C@]1(F)[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QGZHQRNBDZDKFW-FJGDRVTGSA-N 0.000 description 1
- PTESHFKYBQMNFR-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 PTESHFKYBQMNFR-FJGDRVTGSA-N 0.000 description 1
- KLVQSNKMLGBSHV-GIWSHQQXSA-N [(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F KLVQSNKMLGBSHV-GIWSHQQXSA-N 0.000 description 1
- 201000010275 acute porphyria Diseases 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000046970 human APLP1 Human genes 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 102000049632 human CST3 Human genes 0.000 description 1
- 102000051539 human HAVCR1 Human genes 0.000 description 1
- 102000047202 human LCN2 Human genes 0.000 description 1
- 102000052074 human MMP7 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 125000001921 locked nucleotide group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 208000018731 motor weakness Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252919P | 2021-10-06 | 2021-10-06 | |
| US63/252,919 | 2021-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202329984A true TW202329984A (zh) | 2023-08-01 |
Family
ID=84331708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111137690A TW202329984A (zh) | 2021-10-06 | 2022-10-04 | 作為急性肝紫質症（ａｈｐ）之生物標記的腎損傷生物標記 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240360454A1 (https=) |
| EP (1) | EP4413378A1 (https=) |
| JP (1) | JP2024537202A (https=) |
| TW (1) | TW202329984A (https=) |
| WO (1) | WO2023060064A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118460654B (zh) * | 2024-07-10 | 2025-02-14 | 凯莱英医药集团（天津）股份有限公司 | 一种Givosiran的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| LT3052628T (lt) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Kompozicijos ir būdai alas1 geno raiškai nuslopinti |
| WO2021046329A1 (en) * | 2019-09-05 | 2021-03-11 | Octave Bioscience, Inc. | Biomarkers for predicting multiple sclerosis disease activity |
-
2022
- 2022-10-04 WO PCT/US2022/077511 patent/WO2023060064A1/en not_active Ceased
- 2022-10-04 JP JP2024520992A patent/JP2024537202A/ja active Pending
- 2022-10-04 EP EP22802413.9A patent/EP4413378A1/en active Pending
- 2022-10-04 TW TW111137690A patent/TW202329984A/zh unknown
-
2024
- 2024-04-01 US US18/623,281 patent/US20240360454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023060064A1 (en) | 2023-04-13 |
| JP2024537202A (ja) | 2024-10-10 |
| EP4413378A1 (en) | 2024-08-14 |
| US20240360454A1 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10228378B2 (en) | Diagnostic and therapeutic methods and products related to anxiety disorders | |
| Bugiani et al. | Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease | |
| US20250376514A1 (en) | Signature of tl1a (tnfsf15) signaling pathway | |
| US20150224120A1 (en) | Compositions and methods for treating hyperprolinemia-associated mental disorders | |
| Ma et al. | A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population | |
| JP7665678B2 (ja) | 脊髄性筋萎縮症を処置または予防する方法 | |
| JP7849304B2 (ja) | 補体タンパク質の検出 | |
| WO2017083739A1 (en) | A method for predicting a subject's response to valproic acid therapy | |
| US20190010547A1 (en) | Microrna-122 in metabolic diseases | |
| US20240360454A1 (en) | Renal injury biomarkers as biomarkers for acute hepatic porphyria (ahp) | |
| US20140378388A1 (en) | Treatment of uterine leiomyomata | |
| Elhuseiny et al. | Association Study of Vitamin D Deficiency and its Receptor Gene Polymorphism in Diabetic Nephropathy progression | |
| US20240209367A1 (en) | Inhibitory nucleic acids for factor h family proteins | |
| WO2010042102A1 (en) | Identification of subjects likely to benefit from copper treatment | |
| US20200339987A1 (en) | Assays and methods for determining expression of the lect2 gene | |
| Fujimaki et al. | Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease | |
| Jung et al. | Impact of gene polymorphisms of interleukin-18, transforming growth factor-β, and vascular endothelial growth factor on development of IgA nephropathy and thin glomerular basement membrane disease | |
| Abdulmajeed | Study of the effects of organic cation transporter | |
| de Almeida Callou et al. | Pro198Leu polymorphism in the GPX1 gene has no influence on selenium biomarkers after Brazil nut consumption in rheumatoid arthritis patients | |
| WO2010084668A1 (ja) | ネフローゼ症候群の検査方法、並びにネフローゼ症候群の予防又は治療薬およびそのスクリーニング方法 | |
| Alfaifi et al. | Molecular Variants in SIRT1 Gene Among Saudi Women Diagnosed with Gestational Diabetes Mellitus: A Case-Control Study | |
| KR20250113674A (ko) | 당뇨 위험 예측용 바이오마커, 및 이와 콜레스테롤 섭취를 이용한 당뇨 위험 예측 또는 관리 방법 | |
| Atwan et al. | Association of High Mobility Group Box-1 Gene rs1412125 Single Nucleotide Polymorphism with Diabetic Nephropathy in Type II Diabetic Patients | |
| KR20250113675A (ko) | 당뇨 위험 예측용 바이오마커, 및 이와 비타민 섭취를 이용한 당뇨 위험 예측 또는 관리 방법 | |
| KR20250114173A (ko) | 고혈압 위험 예측용 바이오마커, 및 이를 이용한 고혈압 위험 예측 또는 관리 방법 |